The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines

Molecular and Cellular Endocrinology

Volumn 365, Issue 1, 2013, Pages 1-10

  Lavarone, Elisa ^a   Puppin, Cinzia ^a   Passon, Nadia ^a   Filetti, Sebastiano ^b   Russo, Diego ^c   Damante, Giuseppe ^a,d  

^a UNIVERSITY OF UDINE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Epigenetics; Gene expression; Histone post translational modifications; NIS; Thyroid tumors

Indexed keywords

HISTONE H3; IODINE 125; MESSENGER RNA; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SODIUM IODIDE SYMPORTER; THYROID TRANSCRIPTION FACTOR 1; THYROID TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR PAX8;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; ENZYME INHIBITION; EPIGENETICS; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; NIS GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; THYROID CANCER; TRANSCRIPTION REGULATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IODINE; METHYLATION; NEOPLASM PROTEINS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, MESSENGER; SYMPORTERS; THYROID NEOPLASMS;

EID: 84868444460     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.08.019     Document Type: Article

References (44)

1. Annunziata C.M., O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin. Cancer. Res. 2010, 16(18):4517-4526.
2. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129(4):823-837.
3. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., Fry B., Meissner A., Wernig M., Plath K., Jaenisch R., Wagschal A., Feil R., Schreiber S.L., Lander E.S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125(2):315-326.
4. Caiafa P., Guastafierro T., Zampieri M. Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 2009, 23:672-678.
5. Caiafa P., Zlatanova J. CCCTC-binding factor meets poly(ADP-ribose) polymerase-1. J. Cell. Physiol. 2009, 219:265-270.
6. Chevanne M., Zampieri M., Caldini R., Rizzo A., Ciccarone F., Catizone A., D'Angelo C., Guastafierro T., Biroccio A., Reale A., Zupi G., Caiafa P. Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line. J. Cell. Physiol. 2010, 222(2):401-410.
7. Cohen-Armon M., Visochek L., Rozensal D., Kalal A., Geistrikh I., Klein R., Bendetz-Nezer S., Yao Z., Seger R. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol. Cell. 2007, 25(2):297-308.
8. De La Vieja A., Dohan O., Levy O., Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol. Rev. 2000, 80(3):1083-1105.
9. Di Palma T., De Cristofaro T., D'Ambrosio C., Del Prete D., Scaloni A., Zannini M. Poly(ADP-ribose) polymerase 1 binds to Pax8 and inhibits its transcriptional activity. J. Mol. Endocrinol. 2008, 41(5):379-388.
10. - symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab. 2001, 86(6):2697-2700.
11. Dohan O., Carrasco N. Thyroidal iodide transport and thyroid cancer. Cancer Treat. Res. 2004, 122:221-236.
12. Durante C., Puxeddu E., Ferretti E., Molisi R., Moretti S., Bruno R., Barbi F., Avenia N., Scipioni A., Verrienti A., Tosi E., Cavaliere A., Gulino A., Filetti S., Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 2007, 92(7):2840-2843.
13. Füllgrabe J., Kavanagh E., Joseph B. Histone onco-modifications. Oncogene. 2011, 30(31):3391-3403.
14. Jagtap P., Szabo' C. Poly(ADP-ribose) polymerase ad the therapeutic effects of its inhibitors. Nat. Rev. Drug. Discover. 2005, 4(5):421-440.
15. Kogai T., Hershman J.M., Motomura K., Endo T., Onaya T., Brent G.A. Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells. Endocrinology. 2001, 142(8):3369-3379.
16. Kolthur-Seetharam U., Dantzer F., McBurney M.W., de Murcia G., Sassone-Corsi P. Control of AIF mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell. Cycle. 2006, 5:873-877.
17. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J. Clin. Endocrinol. Metab. 1999, 84(9):3228-3234.
18. Li W., Venkataraman G.M., Ain K.B. Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor. J. Clin. Endocrinol. Metab. 2007, 92(3):1080-1087.
19. Li W., Ain K.B. Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells. Endocr. Relat. Cancer. 2010, 17(2):383-398.
20. Madison D.L., Stauffer D., Lundblad J.R. The PARP inhibitor PJ34 causes a PARP-1 indipedent, p21 dependent mitotic arrest. DNA Repair (Amst). 2011, 10(10):1003-1013.
21. Maeda Y., Hunter T.C., Loudy D.E., Davé V., Schreiber V., Whitsett J.A. PARP-2 interacts with TTF-1 and regulates expression of surfactant protein-B. J. Biol. Chem. 2006, 281(14):9600-9606.
22. Mangerich A., Bürkle A. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int. J. Cancer. 2011, 128(2):251-265.
23. Mikkelsen T.S., Ku M., Jaffe D.B., Issac B., Lieberman E., Giannoukos G., Alvarez P., Brockman W., Kim T.K., Koche R.P., Lee W., Mendenhall E., O'Donovan A., Presser A., Russ C., Xie X., Meissner A., Wernig M., Jaenisch R., Nusbaum C., Lander E.S., Bernstein B.E. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007, 448(7153):553-560.
24. O'Brien T., Stokoe D. Converting cancer mutations into therapeutic opportunities. EMBO Mol. Med. 2009, 1(6-7):297-299.
25. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin. Cancer. Res. 2010, 16(18):4527-4531.
26. Pokholock D.K., Harbison C.T., Levine S., Cole M., Hannett N.M., Lee T.I., Bell G.W., Walker K., Rolfe P.A., Herbolsheimer E., Zeitlinger J., Lewitter F., Gifford D.K., Young R.A. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell. 2005, 122(4):517-527.
27. Rando O.J. Global patterns of histone modifications. Curr. Opin. Genet. Dev. 2007, 17(2):94-99.
28. Riesco-Eizaguirre G., Rodríguez I., De la Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer. Res. 2009, 69(21):8317-8325.
29. Robbins J., Merino M.J., Boice J.D., Ron E., Ain K.B., Alexander H.R., Norton J.A., Reynolds J. Thyroid cancer: a lethal endocrine neoplasm. Ann. Intern. Med. 1991, 115(2):133-147.
30. Roh, T.Y., Cuddapah, S., Cui, K., Zhao, K. 2006. The genomic landscape of histone modifications in human T cells. Proc. Natl. Acad. Sci. U S A. 103(43), 15782-7.
31. Russo D., Damante G., Puxeddu E., Durante C., Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endocrinol. 2011, 46(3):R73-R81.
32. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., Schreiber S.L., Mellor J., Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature. 2002, 419(6905):407-411.
33. Schlumberger M., Lacroix L., Russo D., Filetti S., Bidart J.M. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3(3):260-269.
34. Schwartz Y.B., Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature. Rev. Genet. 2007, 8(1):9-22.
35. Schweppe R.E., Klopper J.P., Klorch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell lone redundancy and misidentification. J. Clin. Endocrinol. Metab. 2008, 93(11):4331-4341.
36. Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., Wang Q., Chia D., Goodglick L., Kurdistani S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174(5):1619-1628.
37. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutant. Res. 2008, 647(1-2):21-29.
38. Sparmann A., van Lohuizen M. Plycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer. 2006, 6(11):846-856.
39. Taki K., Kogai T., Kanamoto Y., Hershman J.M., Brent G.A. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3'-5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol. Endocrinol. 2002, 16(10):2266-2282.
40. Tonini T., D'Andrilli G., Fucito A., Gaspa L., Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J. Cell. Physiol. 2008, 214(2):295-300.
41. Trapasso F., Iuliano R., Chiefari E., Arturi F., Stella A., Filetti S., Fusco A., Russo D. Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur. J. Endocrinol. 1999, 140(5):447-451.
42. Tsang D.P., Cheng A.S. Epigenetic regulation of signalling pathways in cancer: role of histone methyltransferase EZH2. J. Gastroenterol. Hepatol. 2011, 26(1):19-27.
43. Tucker C.L., Fields S. Lethal combinations. Nat. Genet. 2003, 35(3):204-205.
44. Weiss S.J., Philp N.J., Grollman E.F. Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984, 114:1090-1098.